α-synuclein (α-syn) is a synaptic protein in which four mutations (A53T, A30P, E46K and gene triplication) have been found to cause an autosomal dominant form of Parkinson’s disease (PD). It is also the major component of intraneuronal protein aggregates, designated as Lewy bodies (LBs), a prominent pathological hallmark of PD. How α-syn contributes to LB formation and PD is still not well-understood. It has been proposed that aggregation of α-syn contributes to the formation of LBs, which then leads to neurodegeneration in PD. However, studies have also suggested that aggregates formation is a protective mechanism against more toxic α-syn oligomers. In this study, we have generated α-syn mutants that have increased propensity to form aggregates by attaching a CL1 peptide to the C-terminal of α-syn. Data from our cellular study suggest an inverse correlation between cell viability and the amount of α-syn aggregates formed in the cells. In addition, our animal model of PD indicates that attachment of CL1 to α-syn enhanced its toxicity to dopaminergic neurons in an age-dependent manner and induced the formation of Lewy body-like α-syn aggregates in the substantia nigra. These results provide new insights into how α-syn-induced toxicity is related to its aggregation.
References
[1]
Pollanen MS, Dickson DW, Bergeron C (1993) Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 52: 183.191
[2]
Galvin JE, Lee VM, Schmidt ML, Tu PH, Iwatsubo T (1999) Pathobiology of the Lewy body. Adv Neurol 80: 313.324
[3]
Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson’s disease. Neuron 66: 646.661
[4]
Savitt JM, Dawson VL, Dawson TM (2006) Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116: 1744.1754
Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95: 6469.6473
[7]
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839.840
[8]
Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 364: 1167.1169
[9]
Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet 18: 106.108
[10]
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276: 2045.2047
[11]
Singleton AB, Farrer M, Johnson J, Singleton A, Hague S (2003) alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302: 841.
[12]
Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164.173
[13]
Devine MJ, Gwinn K, Singleton A, Hardy J (2011) Parkinson’s disease and alpha-synuclein expression. Mov Disord.
[14]
Conway KA, Harper JD, Lansbury PT Jr (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson’s disease are typical amyloid. Biochemistry 39: 2552.2563
[15]
Conway KA, Lee SJ, Rochet JC, Ding TT, Harper JD (2000) Accelerated oligomerization by Parkinson’s disease linked alpha-synuclein mutants. Ann N Y Acad Sci 920: 42.45
[16]
Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 97: 571.576
[17]
Giasson BI, Uryu K, Trojanowski JQ, Lee VM (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 274: 7619.7622
[18]
Li J, Uversky VN, Fink AL (2001) Effect of familial Parkinson’s disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40: 11604.11613
[19]
Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287: 1265.1269
Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA (2003) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson’s disease. Neuron 37: 583.595
Waxman EA, Giasson BI (2009) Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim Biophys Acta 1792: 616.624
[24]
Xie W, Wan OW, Chung KK (2010) New insights into the role of mitochondrial dysfunction and protein aggregation in Parkinson’s disease. Biochim Biophys Acta 1802: 935.941
[25]
Chen L, Periquet M, Wang X, Negro A, McLean PJ (2009) Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 119: 3257.3265
[26]
Chen L, Feany MB (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8: 657.663
[27]
Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH (2006) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington’s and Parkinson’s diseases. Proc Natl Acad Sci U S A 103: 4246.4251
[28]
Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson’s disease. Science 317: 516.519
[29]
Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108: 4194.4199
[30]
Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552.1555
[31]
Link CD, Fonte V, Hiester B, Yerg J, Ferguson J (2006) Conversion of green fluorescent protein into a toxic, aggregation-prone protein by C-terminal addition of a short peptide. J Biol Chem 281: 1808.1816
[32]
Fredenburg RA, Rospigliosi C, Meray RK, Kessler JC, Lashuel HA (2007) The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 46: 7107.7118
[33]
Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300: 636.640
[34]
Hong DP, Fink AL, Uversky VN (2009) Smoking and Parkinson’s disease: does nicotine affect alpha-synuclein fibrillation? Biochim Biophys Acta 1794: 282.290
[35]
Ono K, Mochizuki H, Ikeda T, Nihira T, Takasaki JI (2011) Effect of melatonin on alpha-synuclein self-assembly and cytotoxicity. Neurobiol Aging.
[36]
Hoyer W, Antony T, Cherny D, Heim G, Jovin TM (2002) Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol 322: 383.393
[37]
Hoyer W, Cherny D, Subramaniam V, Jovin TM (2004) Rapid self-assembly of alpha-synuclein observed by in situ atomic force microscopy. J Mol Biol 340: 127.139
[38]
Bartels T, Choi JG, Selkoe DJ (2011) alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477: 107.110
[39]
Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S (2012) Alpha-synuclein in the central nervous system and from erythrocytes, mammalian cells and E. coli exists predominantly as a disordered monomer. J Biol Chem.
[40]
Kim J (1997) Evidence that the precursor protein of non-A beta component of Alzheimer’s disease amyloid (NACP) has an extended structure primarily composed of random-coil. Mol Cells 7: 78.83
[41]
Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr (1996) NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry 35: 13709.13715
[42]
Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4: 160.164
[43]
Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ (2008) Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 28: 7687.7698
[44]
Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985.989
[45]
Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H (2002) Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 3: 583.588
[46]
Lou H, Montoya SE, Alerte TN, Wang J, Wu J (2010) Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem 285: 17648.17661
[47]
Jin W, Ge WP, Xu J, Cao M, Peng L (2006) Lipid binding regulates synaptic targeting of PICK1, AMPA receptor trafficking, and synaptic plasticity. J Neurosci 26: 2380.2390
[48]
Tiscornia G, Singer O, Verma IM (2006) Production and purification of lentiviral vectors. Nat Protoc 1: 241.245
